A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

NCT01990534 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin

Sponsor

Millennium Pharmaceuticals, Inc.